Sun Pharma Launches Leqselvi (Deuruxolitinib) to Treat Severe Alopecia Areata in the US

Shots: Sun Pharma has launched Leqselvi (deuruxolitinib; 8mg) for the treatment of pts with severe alopecia areata in the US FDA Approval was based on 2 P-III (THRIVE-AA1 & THRIVE-AA2) trials that assessed the scalp hair regrowth using the SALT score with Leqselvi (8 or 12mg, BID) vs PBO in adults (n=1223; 18-65yrs.) with severe alopecia areata…

ByDipanshu DixitJuly 15, 2025

News

BI Collaborates with LEO Pharma to Commercialize & Develop Spevigo

Shots: LEO Pharma has entered into an exclusive global license & transfer agreement with BI to commercialize & advance the development of Spevigo (spesolimab) As per the deal, LEO Pharma will handle commercialization & further development of Spevigo in exchange for $105.18M (€90M) upfront, along with milestones & tiered royalties; closing expected in H2’25, subject…

ByRidhi RastogiJuly 14, 2025

Weekly Snapshot

PharmaShots Weekly Snapshots (Jun 07, 2025 – Jul 11, 2025)   

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, M&A, and Biosimilars. Check out our full report below:  PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy  Read More: PulseSight Therapeutics BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with…

ByRidhi RastogiJuly 11, 2025

News

Eolas Therapeutics Joins Forces with AstraZeneca to Develop AZD4041

Shots: Eolas Therapeutics has secured full development rights from AstraZeneca for AZD4041 to treat opioid use disorder (OUD) and other substance use disorders; terms remain confidential As per the agreement, Eolas will take full responsibility for AZD4041 under the existing IND and advance it to P-II trials with NIDA UG3 support, focusing on a patient-centered…

ByDipanshu DixitJuly 11, 2025

News

AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

Shots: AbbVie and IGI Therapeutics, a subsidiary of Ichnos Glenmark Innovation, have entered into an exclusive licensing deal for ISB 2001, a drug targeting oncology & autoimmune diseases developed using IGI's proprietary BEAT protein platform As per the deal, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe,…

ByDipanshu DixitJuly 11, 2025

News

Biocytogen Pharmaceuticals Enters a Licensing Agreement with BeOne Medicines for Multiple Antibody Candidates

Shots: Biocytogen & BeOne have entered into a global licensing agreement for multiple fully human antibodies discovered using Biocytogen’s RenMicefully human antibody platform As per the deal, Biocytogen will receive an upfront payment, development, regulatory, & commercial milestones, with net sales-based tiered royalties on licensed products. Although, financial terms remain undisclosed Collaboration builds on BeOne Medicines…

ByRidhi RastogiJuly 10, 2025

News

Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines

Shots: JCR Pharmaceuticals & Alexion have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines As per the deal, Alexion may use licensed capsids from the JUST-AAV platform in up to 5 genomic medicine programs in exchange for an undisclosed upfront payment, ~$225M in R&D milestones, ~$600M in sales milestones (milestones…

ByRidhi RastogiJuly 9, 2025

News

Chugai Pharmaceutical Partners with Gero to Develop Age-Related Disease Therapies

Shots: Chugai Pharmaceutical has entered into a joint research & license agreement with Gero to develop novel therapies for age-related diseases Chugai will develop novel antibody drugs using its proprietary antibody engineering techs for novel targets discovered by Gero's AI target discovery platform, & obtain exclusive global rights to research, develop, manufacture, & commercialize antibodies…

ByRidhi RastogiJuly 8, 2025

Weekly Snapshot

PharmaShots Weekly Snapshots (Jun 30, 2025 – Jul 04, 2025)   

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, and Biosimilar. Check out our full report below:  Neurocrine Reports Data From KINECT-HD Study Evaluating INGREZZA in Huntington’s Disease (HD) Read More: Neurocrine UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients Read More: UCB …

ByRidhi RastogiJuly 4, 2025

News

Brii Biosciences Enters a Licensing Deal with Joincare Pharmaceutical for BRII-693 to Treat Bacterial Infections

Brii Biosciences has entered into a license & technology transfer agreement with Joincare to develop & commercialize BRII-693 in the Greater China region As per the deal, Joincare will handle development, regulatory activities & commercialization of BRII-693 in Greater China in exchange for an upfront payment as well as development & commercial milestones, with net…

ByRidhi RastogiJuly 4, 2025

Sun Pharma Launches Leqselvi (Deuruxolitinib) to Treat Severe Alopecia Areata in the US

BI Collaborates with LEO Pharma to Commercialize & Develop Spevigo

PharmaShots Weekly Snapshots (Jun 07, 2025 – Jul 11, 2025)

Eolas Therapeutics Joins Forces with AstraZeneca to Develop AZD4041

AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

Biocytogen Pharmaceuticals Enters a Licensing Agreement with BeOne Medicines for Multiple Antibody Candidates

Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines

PharmaShots Weekly Snapshots (Jun 30, 2025 – Jul 04, 2025)

Brii Biosciences Enters a Licensing Deal with Joincare Pharmaceutical for BRII-693 to Treat Bacterial Infections

Contact US

OUR INFORMATION

FOLLOW US